A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults

Inclusion Criteria: 1. Adults ≥ 18 years 2. Negative results of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) 3. Healthy or medically stable participants 4. Contraceptive within 365 days post dosing Exclusion Criteria: 1. Medical condition: * Known hypersensitivity to monoclonal antibody (mAb) or investigational product (IP) component. * Acute illness including fever on the day prior to or day of dosing. * Any other significant disease increase the risk to participant study. 2. Laboratory related: * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2.0 × upper limit of normal (ULN), alkaline phosphatase (ALP) \> 1.5 × ULN, or TBL (total bilirubin) \> 1.5 × ULN (unless due to Gilbert's syndrome). * Serum creatinine \> 176 μmol/L. * Haemoglobin \< 10g/dL. * Platelet count \< 100 × 10\^3/μL. * White blood cell count \< 3.5 × 10\^3/μL or neutrophil count \< 1.5 × 10\^3/μL. * Other laboratory significantly abnormal in the screening panel that, in the opinion of the investigator, will increase participants risk or might confound analysis of study results. 3. COVID-19 infection history/any receipt of mAb indicated for COVID-19. 4. Prior/concomitant treatment: Receipt of any investigational product within 90 days or 5 antibody half-lives (whichever is longer) prior to Day 1